SHP2抑制作为单药及联合JAK2抑制在骨髓增殖性肿瘤临床前模型中的疗效
在骨髓增殖性肿瘤(MPN)临床前模型中,SHP2抑制剂RMC-4550单药可抑制MPN细胞生长并改善小鼠生存,与JAK2抑制剂鲁索替尼联用可增强对鲁索替尼持续存活细胞的生长抑制、促进ERK失活和凋亡,并较鲁索替尼单药进一步抑制疾病和延长生存。
要点
- SHP2抑制剂RMC-4550与鲁索替尼联用显著增强MPN细胞系生长抑制。
- RMC-4550可抑制MPN患者造血祖细胞的肿瘤性生长并与鲁索替尼协同。
- RMC-4550联合鲁索替尼较鲁索替尼单药进一步抑制疾病并延长小鼠生存。
核心结论
- SHP2是候选治疗靶点,有潜力快速转化至临床评估以改善MPN患者的现有靶向治疗。
研究设计与样本
- 临床前研究,使用MPN细胞系、MPN患者造血祖细胞及由MPL-W515L驱动的MPN小鼠模型。
主要发现
- SHP2抑制剂RMC-4550与JAK2抑制剂鲁索替尼联用显著增强MPN细胞系生长抑制,并有效防止鲁索替尼持续生长。
- 已建立的鲁索替尼持续存活细胞的生长和活力仍对SHP2抑制敏感。
- SHP2和JAK2抑制均降低细胞RAS-GTP水平,两者同时抑制增强ERK失活并增加凋亡。
- RMC-4550抑制MPN患者造血祖细胞的肿瘤性生长,并与鲁索替尼表现出协同作用。
- RMC-4550拮抗MPN表型并增加MPL-W515L驱动MPN小鼠模型的生存;RMC-4550联合鲁索替尼在健康小鼠中安全且耐受,较鲁索替尼单药进一步抑制疾病,包括延长生存。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为临床前研究,结论基于细胞系、患者造血祖细胞和MPL-W515L小鼠模型。
- 原文指出SHP2抑制剂正在实体瘤患者中进行临床评估,本研究发现为临床前结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocytosis, and primary myelofibrosis, are clonal hematopoietic neoplasms driven by mutationally activated signaling by the JAK2 tyrosine kinase. Although JAK2 inhibitors can improve MPN patients' quality of life, they do not induce complete remission as disease-driving cells persistently survive therapy. ERK activation has been highlighted as contributing to JAK2 inhibitor persistent cell survival. As ERK is a component of signaling by activated RAS proteins and by JAK2 activation, we sought to inhibit RAS activation to enhance responses to JAK2 inhibition in preclinical MPN models. We found the SHP2 inhibitor RMC-4550 significantly enhanced growth inhibition of MPN cell lines in combination with the JAK2 inhibitor ruxolitinib, effectively preventing ruxolitinib persistent growth, and the growth and viability of established ruxolitinib persistent cells remained sensitive to SHP2 inhibition. Both SHP2 and JAK2 inhibition diminished cellular RAS-GTP levels, and their concomitant inhibition enhanced ERK inactivation and increased apoptosis. Inhibition of SHP2 inhibited the neoplastic growth of MPN patient hematopoietic progenitor cells and exhibited synergy with ruxolitinib. RMC-4550 antagonized MPN phenotypes and increased survival of an MPN mouse model driven by MPL-W515L. The combination of RMC-4550 and ruxolitinib, which was safe and tolerated in healthy mice, further inhibited disease compared to ruxolitinib monotherapy, including extending survival. Given SHP2 inhibitors are undergoing clinical evaluation in patients with solid tumors, our preclinical findings suggest that SHP2 is a candidate therapeutic target with potential for rapid translation to clinical assessment to improve current targeted therapies for MPN patients.
引用
- Pandey G, Mazzacurati L, Rowsell TM, et al. SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms. Am J Hematol. 2024. PMID: 38440831. doi:10.1002/ajh.27282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。